LYEL

Lyell Immunopharma, Inc. is a cutting-edge biopharmaceutical company headquartered in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington. The company specializes in pioneering T-cell reprogramming technologies designed to formulate innovative therapies targeting solid tumors, thereby enhancing the effectiveness and longevity of T-cell treatments. With its proprietary platforms and a strong commitment to meeting significant unmet medical needs in oncology, Lyell is well-positioned to transform cancer treatment and play a critical role in the evolving immuno-oncology sector.